Citius Oncology ships first international order of LYMPHIR to Europe

Citius Pharmaceuticals, Inc.

First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.
Product will be available via Named Patient Programs under applicable local regulations.
LYMPHIR approved by FDA in August 2024 for relapsed/refractory CTCL; U.S. commercial launch in December 2025.
Citius Oncology (Nasdaq: CTOR) is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).
International expansion complements ongoing U.S. launch progress with formulary access and payer coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.